Praxis Precision Medicines Inc.
Praxis Precision Medicines, Inc. 2024 Annual Meeting Stockholder Actions
Summary
On June 5, 2024, Praxis Precision Medicines, Inc. held its Annual Meeting of Stockholders where the stockholders elected Dean Mitchell and Jill DeSimone as Class I Directors, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm, approved the amendment and restatement of the 2020 Stock Option and Incentive Plan to increase the total number of shares available for issuance by 870,000 shares, and approved, on an advisory basis, the compensation of the Company's named executive officers.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement